Fewer than 30% of health system leaders said they earned significant return on investment from virtual care offerings, ...

Former Congressional Budget Office Director Dan Crippen argues the 340B discount program is overdue for reform.

Drugs that will be subject to rebates in 340B next year include Bristol Myers Squibb’s Eliquis, Johnson & Johnson’s Stelara ...

The hospital operator will invest more in organic hospital growth and high-acuity service lines as it sees strong demand for ...

Dr. Cliff Deveny announced the transition less than a month after General Catalyst finalized its $515 million acquisition of ...

Overall, Cigna expects earnings to grow next year after posting a solid third quarter. But investments in a new PBM model and ...

The goodwill impairment charge is meant to realign Centene’s value on its own books with it value in the market, which has ...

Measuring financial returns from AI can be challenging, experts said at the HLTH conference last week. But other metrics, ...

The healthcare giant beat Wall Street expectations in the third quarter, but reported a net loss after recording a $5.7 ...

The operator increased its outlook after posting earnings growth in the third quarter, aided by strong demand for services in ...

The massive PBM’s announcement comes as the drug middlemen attempt to lessen regulatory scrutiny. The company also said it ...

The company has started to score insurers on their success in making rate data available online. Large payers tend to do ...